Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, r...

Novartis AG (NVS) has a valuation score of 80/100 (strong), profitability score of 87/100 (strong), financial health score of 74/100 (moderate), Piotroski F-Score of 6/9, Altman Z-Score of 4.44 (safe zone), revenue growth of +9.1% YoY.

Neutral

Analyst Consensus

Hold

Wall Street consensus estimates — not a PMP forecast · Updated Sep 1, 2026

Analyst Recommendations34 analysts · 2026-08-01
6
10
14
4
Strong Buy 6Buy 10Hold 14Sell 4Strong Sell 0

Recent Market Moves

See all NVS moves →
DateSessionPriceMoveZ-Score
Sep 1Pre-market$162.11+6.61%4.36
Sep 1Regular$161.32+6.09%4.03
Sep 1After-hours$161.86+6.44%4.26
Novartis AG (NVS) Valuation & P/E History →Novartis AG (NVS) Financial Statements →
Share:

Explore More Stocks

AAPLMSFTNVDAGOOGLAMZNMETATSLAJPMWMTVView all stocks →